N
MDGL icon

Natixis’s Madrigal Pharmaceuticals MDGL Stock Holding History

Natixis’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,041
Closed -$606K – 1240
2025
Q4 		$606K Buy
+1,041
New +$532K ﹤0.01% 802
2024
Q1 		– Sell
-857
Closed -$198K – 1139
2023
Q4 		$198K Sell
857
-45
-5% -$7.87K ﹤0.01% 717
2023
Q3 		$132K Buy
+902
New +$170K ﹤0.01% 757
2023
Q2 		– Sell
-1,109
Closed -$269K – 1091
2023
Q1 		$269K Buy
+1,109
New +$302K ﹤0.01% 709
2021
Q2 		– Sell
-22,000
Closed -$2.57M – 915
2021
Q1 		$2.57M Sell
22,000
-31,722
-59% -$3.7M 0.01% 638
2020
Q4 		$5.97M Sell
53,722
-25,412
-32% -$3.11M 0.02% 484
2020
Q3 		$9.4M Buy
+79,134
New +$8.59M 0.07% 196

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Natixis's MDGL Position: Q1 2026 in Review

Natixis sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 1,041 shares — an estimated $606K sold.

Natixis first reported a position in MDGL in Q3 2020 and held it in 7 quarters. The position peaked at $9.4M in Q3 2020. 380 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Natixis reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Natixis sold 1,041 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $606K.
  • Natixis first reported a position in Madrigal Pharmaceuticals in Q3 2020 and held it in 7 quarters.
  • Natixis's Madrigal Pharmaceuticals position peaked at $9.4M in Q3 2020.
  • 380 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.